FEEL CONFIDENT IN YOUR ACCESS TO PARSABIV® FOR
CLINICALLY APPROPRIATE PATIENTS WHO NEED IT.
Understanding ESRD reimbursement to enhance planning for patient care
Parsabiv® is reimbursed as part of the ESRD bundle for Medicare Fee-for-Service (FFS) beneficiaries 1
Calcimimetics, including Parsabiv®, were the first class of drugs to go through the Transitional Drug Add-on Payment Adjustment (TDAPA), 3 setting the precedent for access to ESRD therapies established under TDAPA.
When a therapy is added to the ESRD PPS bundle, its valuation is based on utilization under TDAPA 10
Average Parsabiv® utilization of~6.3%
of dialysis sessions in Q3 2018-Q4 2019 2
That’s roughly 6 patients out of 100
Amount added to the bundle for calcimimetics, including Parsabiv®, in 2021 1
The addition means providers receive the same $10.09 calcimimetics reimbursement, whether patients are taking Parsabiv® or not 1
Since most patients are not prescribed Parsabiv®, the bundle addition supports patient access to Parsabiv®.
supports patient access to Parsabiv®.
Reflects a $9.93 calcimimetic valuation plus a market basket increase of 1.6%.
CMS = Center for Medicare and Medicaid Services; ESRD = End-Stage Renal Disease; PPS = Prospective Payment System.
Reimbursement for Parsabiv®, and other dialysis costs, is adjusted annually by a market basket increase to the ESRD bundle rate. 1
Periodic rebasing of the ESRD market basket occurs to reflect a more up-to-date cost structure 4.
Frequently asked questions
How are different organizations being impacted now that Parsabiv® reimbursement has been added to the bundle?
Now that Parsabiv® is reimbursed as part of the ESRD bundle, some organizations are limiting access. Dialysis organizations can think about reimbursement across all dialysis patients since the additional amount for calcimimetics is there for every single dialysis session, not just for dialysis sessions for patients prescribed Parsabiv®. Based on utilization at ~6.3% of dialysis sessions during the evaluation period, the $10.09 added to the ESRD bundle is designed to cover Parsabiv® for clinically appropriate patients. This amount is expected to grow annually with the bundle base rate increase.
How does being in the bundle impact patient out-of-pocket costs?
The portion of the bundle not covered by Medicare will increase by the same percentage that the bundle increases to account for the cost of Parsabiv® and other dialysis costs. Reimbursement for Parsabiv®–and other dialysis costs–is adjusted annually by a market basket increase to the ESRD bundle. This will likely impact those patients who don’t have a secondary payer source. This Medicare policy is not specific to calcimimetics.
What can I do to get Parsabiv® for patients who really need it?
Talk with your medical director about the patients for whom Parsabiv® is the best fit, and make sure they and your care team understand Parsabiv® reimbursement. You can also reach out to your Parsabiv® representative on how to help start a conversation with your medical director for them to understand the reimbursement dynamics of Parsabiv®.
Contact your Parsabiv® account manager for more information about reimbursement and how we can support you and your care team.
Medicare Advantage (MA)
MA plans receive capitated payments to provide all Medicare‐covered services to pay enrollees, and they are responsible for covering calcimimetics for clinically appropriate patients. Coverage and reimbursement will vary based on an individual organization’s payer contracts. Reach out to your contracted payer or parent organization to determine how Parsabiv® will be covered. Getting coverage for Parsabiv® may require amending your dialysis organization’s payer contracts. Work with your contracting group to make the case for coverage for clinically appropriate patients when contracts are being negotiated.
Medicaid coverage varies by state. Check with your State Medicaid Office to understand coverage and requirements specific to your state.
Commercial coverage and reimbursement will vary. Verify payment details once you have identified clinically appropriate patients. Reach out to your contracted payer or parent organization to determine how Parsabiv® will be covered under your specific contract terms; contract amendments may be necessary. Work with your contracting group to make the case for coverage for clinically appropriate patients when contracts are being negotiated.
We continue to be committed to helping patients access Amgen medicines whenever possible
Financial support options for any insurance type
Whatever type of insurance your patients have–even if they have none–we can help you understand how their Amgen medicine may be covered and refer them to programs that may be able to help them afford their medication, such as Amgen FIRST STEP TM. *
For uninsured patients
Amgen Safety Net Foundation is a nonprofit patient assistance program sponsored by Amgen that helps qualifying patients access Amgen medicines at no cost.
Contact Amgen Assist® at
through Friday, 9:00 am to
8:00 pm ET, for reimbursement
Resources include referrals to independent nonprofit patient assistance programs. Eligibility for resources provided by independent nonprofit patient assistance programs is based on the nonprofits’ criteria. Amgen has no control over these programs and provides referrals as a courtesy only.
*Terms, conditions, and program maximums apply. This program is not open to patients receiving prescription reimbursement under any federal, state, or government-funded healthcare program. Not valid where prohibited by law.
See how Parsabiv® performed
in clinical trials and its use in real-world outcomes
DOSING & MONITORINGSwitching from oral
cinacalcet to Parsabiv® (etelcalcetide)
See an analysis from
hundreds of real-world treatment experiences